# PCR-MIB (NCT02662062)

> Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02662062
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Australian and New Zealand Urogenital and Prostate Cancer Trials Group
- Conditions: Bladder Cancer
- Interventions: Pembrolizumab; Cisplatin; Radiotherapy
- Enrollment: 28
- Primary outcome: The Number of Participants Experiencing an Unacceptable Level of Toxicity as Defined Below

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=pcr-mib-nct02662062